WebIreland and Northern Ireland . Consult Summary of Product Characteristics (SmPC) before prescribing. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information . Presentation: Hard capsules containing pomalidomide 1mg, 2mg, 3mg or 4mg Indications: WebThe HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent … Medicines Shortages - Find a medicine - HPRA Generic / Interchangeable List - Find a medicine - HPRA About Us - Find a medicine - HPRA ATC Codes - Find a medicine - HPRA Regulatory Information - Find a medicine - HPRA Merck Sharp & Dohme Ireland SmPC PIL : Synflorix (EU/1/09/508/1-9) … Veterinary Medicines Information - Find a medicine - HPRA Publications & Forms - Find a medicine - HPRA Contact Us - Find a medicine - HPRA News and Events - Find a medicine - HPRA
Find a Medicine Results - HPRA
WebWelcome to emc northern ireland. This site contains Northern Ireland-specific medicines information for healthcare professionals and patients. Following Brexit, medicines used in … WebIreland Dermatology Adtralza ® (tralokinumab) SmPC and PIL Dovobet ® gel (calcipotriol + betamethasone dipropionate) SmPC and PIL Dovonex ® cream (calcipotriol) SmPC and PIL Dovonex ® ointment (calcipotriol) SmPC and PIL Enstilar ® cutaneous foam (calcipotriol+ betamethasone dipropionate) SmPC and PIL Fucibet ® cream fbyg winchester va
Summary of product characteristics European …
WebThis site contains Northern Ireland-specific medicines information for healthcare professionals and patients. Following Brexit, medicines used in Northern Ireland can either be approved by the European Medicines Agency (EMA) or the UK's Medicines & Healthcare products Regulatory Agency (MHRA). ... SmPC. Updated. Xolair 150 mg solution for ... WebThe summary of product characteristics document (known as SPC) is also provided for each medicine. The SPC is typically used by healthcare professionals. The package leaflet which includes information for patients and members of the public is … WebRefer to the SmPC for recommended dose modifications based on cytopaenias. Serious infections including events of sepsis with fatal outcome have been reported. Monitoring of signs and symptoms of infection is required. Suspected infections require prompt treatment, including antimicrobials and dose interruption or reduction as appropriate. fbyh80-1.0/50s